19 completed, 3 terminated, 1 recruiting, 1 suspended. 12 Phase 1, 11 Phase 2, 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 12 | Completed 10, Suspended 1, Withdrawn 1 |
| Phase 2 | 11 | Completed 8, Terminated 2, Suspended 1 |
| Phase 3 | 3 | Completed 1, Recruiting 1, Terminated 1 |
Follow SymBio Pharmaceuticals: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 3 Trial to Compare IV BCV Versus IV CDV for Treatment of Adenovirus Infection After Allo-HCT cidofovir, Brincidofovir - Adenovirus Infections | Phase 3 | Recruiting | SymBio Pharmaceuticals | 180 | 2026-03-17 | 2026-10-19 |
| A Phase 1b/2 Study of Intravenous Brincidofovir in Patients With Relapsed or Refractory Lymphoma and Relapsed or Refractory Extranodal Natural Killer/T-cell Lymphoma Brincidofovir - Relapsed or Refractory Lymphoma Including ENKL | Phase 1 / Phase 2 | Suspended | SymBio Pharmaceuticals | 43 | 2025-06-09 | 2026-02-05 |
| Study to Confirm of the Safety and Tolerability of Brincidofovir in Subjects With BK Virus Infection (Viremia) After Kidney Transplantation Brincidofovir - BK Virus Infection, Nephropathy | Phase 2 | Terminated | SymBio Pharmaceuticals | 1 | 2022-10-14 | 2024-12-04 |
| A Phase 2a Study of IV BCV in Subjects With Adenovirus Infection BCV - Adenovirus Infections, Cytomegalovirus Infection | Phase 2 | Completed | SymBio Pharmaceuticals | 53 | 2021-08-16 | 2026-08-11 |
| Drug-Drug Interaction Study of Intravenous Administration of SyB V-1901 and Cyclosporine in Japanese Healthy Subjects SyB V-1901, Cyclosporine - Drug Drug Interaction | Phase 1 | Completed | SymBio Pharmaceuticals | 13 | 2020-11-09 | 2021-04-27 |
| Follow-up Study of SyB L-0501 in Combination With Rituximab to Treat DLBCL No intervention - Diffuse Large B Cell Lymphoma | Completed | SymBio Pharmaceuticals | 25 | 2020-03-26 | 2023-04-18 | |
| Phase I/II Study of SyB L-0501RI in Combination With Rituximab to Treat Lymphoma SyB L-0501RI - Lymphoma, B-cell, Diffuse | Phase 1 / Phase 2 | Completed | SymBio Pharmaceuticals | 37 | 2019-04-01 | 2023-11-24 |
| SyB C-0501(Oral Bendamustine) in Patients With Advanced Solid Tumors SyB C-0501 - Advanced Solid Tumor | Phase 1 | Completed | SymBio Pharmaceuticals | 18 | 2018-05-24 | 2021-04-27 |
| Phase III Study of SyB L-0501 in Combination With Rituximab to Treat Recurrent/Relapsed Diffuse Large B-Cell Lymphoma Rituximab - Assess the Efficacy and Safety of SyB L-0501 in Combination With Rituximab in Patients With Recurrent or Relapsed DLBCL | Phase 3 | Completed | SymBio Pharmaceuticals | 40 | 2018-01-15 | 2023-04-18 |
| Study of SyB C-1101 in Patients With Myelodysplastic Syndrome SyB C-1101 - Myelodysplastic Syndrome | Phase 1 | Completed | SymBio Pharmaceuticals | 10 | 2017-10-06 | 2022-11-16 |
| Study of SyB P-1501 (Fentanyl HCI) for Treatment of Postoperative Pain SyB P-1501, SyB P-1501 placebo - Postoperative Pain | Phase 3 | Terminated | SymBio Pharmaceuticals | 49 | 2016-11-21 | 2022-11-17 |
| Combination Therapy of SyB C-1101 and Azacytidine in Patients With Myelodysplastic Syndrome SyB C-1101 and Azacytidine - Myelodysplastic Syndrome | Phase 1 | Withdrawn | SymBio Pharmaceuticals | 2015-12-01 | 2022-11-17 | |
| Long Term Safety Study of SyB L-1101 in Patients With Recurrent/Relapsed or Refractory Myelodysplastic Syndrome (MDS) - Extension Study SyB L-1101 - Myelodysplastic Syndrome | Phase 1 | Completed | SymBio Pharmaceuticals | 1 | 2014-12-01 | 2017-03-31 |
| Long Term Safety Study of SyB C-1101 in Patients With Recurrent/Relapsed or Refractory Myelodysplastic Syndrome (MDS) - Extension Study SyB C-1101 - Myelodysplastic Syndrome | Phase 1 | Completed | SymBio Pharmaceuticals | 1 | 2013-08-01 | 2017-02-23 |
| Safety and Pharmacokinetics Study of SyB C-1101 in Patients With Recurrent/Relapsed or Refractory Myelodysplastic Syndrome (MDS) SyB C-1101 - Myelodysplastic Syndrome | Phase 1 | Completed | SymBio Pharmaceuticals | 10 | 2013-03-01 | 2022-11-21 |
| Efficacy and Safety Study of SyB L-0501 for Patients With Chronic Lymphocytic Leukemia SyB L-0501 - Chronic Lymphocytic Leukemia | Phase 2 | Completed | SymBio Pharmaceuticals | 10 | 2013-01-01 | 2017-02-01 |
| Safety and Pharmacokinetics Study of SyB L-1101 in Patients With Recurrent/Relapsed or Refractory Myelodysplastic Syndrome (MDS) SyB L-1101 - Myelodysplastic Syndrome | Phase 1 | Completed | SymBio Pharmaceuticals | 9 | 2012-06-01 | 2022-11-21 |
| Study of SyB L-0501 to Treat Relapsed/Refractory Multiple Myeloma SyB L-0501 - Relapsed/Refractory Multiple Myeloma | Phase 2 | Completed | SymBio Pharmaceuticals | 17 | 2011-11-01 | 2015-02-06 |
| Efficacy and Safety Study of SyB L-0501 in Combination With Rituximab in Patients With Untreated, Low-grade B Cell Non-Hodgkin's Lymphoma and Mantle Cell Lymphoma SyB L-0501, rituximab - Low-grade B Cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma Where Hematopoietic Stem Cell Transplantation is Not Indicated | Phase 2 | Completed | SymBio Pharmaceuticals | 70 | 2011-11-01 | 2016-04-27 |
| Phase II Study of SyB D-0701 for Radiotherapy-Induced Nausea and Vomiting (RINV) SyB D-0701, Placebo - Radiotherapy-induced Nausea and Vomiting (RINV) | Phase 2 | Completed | SymBio Pharmaceuticals | 189 | 2011-05-01 | 2014-11-19 |
Showing 20 of 25. Sign in to see all of them.
Myelodysplastic Syndromes (6) · Lymphoma (4) · Lymphoma, Large B-Cell, Diffuse (4) · Lymphoma, Non-Hodgkin (4) · Lymphoma, Mantle-Cell (3) · Adenoviridae Infections (2) · Lymphoma, Follicular (2) · Multiple Myeloma (2) · Cytomegalovirus Infections (1) · Dendritic Cell Sarcoma, Interdigitating (1) · Epstein-Barr Virus Infections (1) · Immunoblastic Lymphadenopathy (1) · Kidney Diseases (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Leukemia-Lymphoma, Adult T-Cell (1)
Bendamustine Hydrochloride (5) · Rituximab (5) · brincidofovir (3) · Azacitidine (1) · Cidofovir (1) · Cyclosporine (1) · Prednisolone (1)
Japan (23) · United States (2) · Austria (1) · Belgium (1) · Canada (1) · China (1) · Denmark (1) · France (1) · Germany (1) · Italy (1) · Netherlands (1) · Portugal (1) · Singapore (1) · South Korea (1) · Spain (1)
Katsuhisa Goto (6) · Kensei Tobinai, MD, Ph D (2) · Kensei Tobinai, MD, PhD (2) · Minori Rosales (1) · Shinsuke Iida, MD, Ph D (1) · Takayuki Kawashima (1) · Takeshi Yoshida (1) · Toshihiko Nagase (1)
PMID 35244756, PMID 20594195, PMID 20626754, PMID 35796785, PMID 36331674, PMID 39382091, PMID 40828617